<DOC>
	<DOCNO>NCT00557193</DOCNO>
	<brief_summary>This phase III trial study combination chemotherapy without lestaurtinib see well work treat young patient newly diagnose acute lymphoblastic leukemia . Drugs use chemotherapy work different way stop growth stop cancer cell , either kill cell , stop dividing , stop spread . Lestaurtinib may stop growth cancer cell block enzymes need cell growth . It yet know whether combination chemotherapy effective without lestaurtinib treat acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Lestaurtinib Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate 3-year event-free survival ( EFS ) infant mixed lineage leukemia-rearranged ( MLL-R ) acute lymphoblastic leukemia ( ALL ) treat chemotherapy plus fms-related tyrosine kinase 3 ( FLT3 ) inhibitor lestaurtinib . SECONDARY OBJECTIVES : I . To compare 3-year EFS infant MLL-R ALL treat chemotherapy plus FLT3 inhibitor lestaurtinib MLL-R patient treat chemotherapy alone . II . To determine safe , tolerable biologically active dose lestaurtinib give sequential combination chemotherapy MLL-R infant . III . To characterize pharmacokinetics pharmacodynamics lestaurtinib infant give propose dose sequential combination chemotherapy . IV . To identify molecular mechanism resistance lestaurtinib leukemic blast . V. To describe level minimal residual disease infant ALL within context propose therapy , correlate outcome . VI . To identify gene expression pattern diagnostic infant leukemia sample correlate outcome within context propose therapy . VII . To describe outcome infant MLL-G ALL treat modify P9407 chemotherapy backbone include extended continuation phase . OUTLINE : INDUCTION THERAPY ( WEEKS 1-5 ) : All patient receive induction therapy comprise vincristine sulfate intravenously ( IV ) 1 minute day 8 , 15 , 22 , 29 ; daunorubicin hydrochloride IV 30 minute day 8 9 ; cyclophosphamide IV 30 minute every 12 hour day 3 4 ( close 05/19/09 ) ; pegaspargase asparaginase intramuscularly ( IM ) day 15 , 18 , 22 , 25 , 29 , 33 ; prednisone orally ( PO ) thrice daily ( TID ) methylprednisolone IV day 1-7 ; dexamethasone IV PO TID day 8-28 ; cytarabine IV 30 minute day 8-21 ; methotrexate intrathecally ( IT ) day 1 29 ; cytarabine IT day 15 ; hydrocortisone IT day 15 29 ; filgrastim IV subcutaneously ( SC ) begin day 5 continue blood count recover . Standard-risk patient non-randomly assign receive less intensive chemotherapy regimen without lestaurtinib ( post-induction therapy A ) . POST-INDUCTION THERAPY A : ( standard-risk patient MLL-germline [ G ] ) INDUCTION INTENSIFICATION ( WEEKS 6-9 ) : Patients receive high-dose methotrexate IV continuously 24 hour day 1 8 ; triple IT chemotherapy comprise methotrexate , cytarabine , hydrocortisone day 1 8 ; leucovorin calcium IV PO every 6 hour begin 42 hour start high-dose methotrexate continue methotrexate level &lt; 0.1 uM ; cyclophosphamide IV 30 minute day 15-19 ; etoposide IV 2 hour day 15-19 ; filgrastim IV SC begin day 20 continue blood count recover . Patients morphologic remission proceed re-induction therapy . RE-INDUCTION ( WEEKS 10-12 ) : Patients receive vincristine sulfate IV 1 minute day 1 , 8 , 15 ; daunorubicin hydrochloride IV 30 minute day 1 2 ; cyclophosphamide IV 30 minute every 12 hour day 3 4 ; pegaspargase asparaginase IM day 4 ; dexamethasone IV PO twice daily ( BID ) day 1-7 15-21 ; triple IT chemotherapy comprise methotrexate , cytarabine , hydrocortisone day 1 15 ; filgrastim IV SC begin day 5 continue blood count recover . CONSOLIDATION ( WEEKS 13-19 ) : Patients receive high-dose methotrexate IV continuously 24 hour day 1 8 ; leucovorin calcium IV every 6 hour begin 42 hour start high-dose methotrexate continue methotrexate level &lt; 0.1 uM ; triple IT chemotherapy comprise methotrexate , cytarabine , hydrocortisone day 1 ; etoposide IV 2 hour day 15-19 ; cyclophosphamide IV 30 minute day 15-19 ; high-dose cytarabine IV 3 hour every 12 hour day 29 30 ; pegaspargase asparaginase IM day 30 ; filgrastim IV SC begin day 20 day 31 continue blood count recover . CONTINUATION I ( WEEKS 20-41 ) : Patients receive vincristine sulfate IV day 1 week 20 24 ; dexamethasone IV PO BID day 1-5 week 20 , 24 ; triple IT chemotherapy comprise methotrexate , cytarabine , hydrocortisone day 1 week 20 24 ; methotrexate IV day 1 week 21-24 25-27 ; etoposide IV 2 hour day 1-5 week 28 ; cyclophosphamide IV 30 minute day 1-5 week 28 ; mercaptopurine PO day 1-7 week 21-23 25-27 ; filgrastim SC IV begin day 6 week 28 continue blood count recover . CONTINUATION II ( WEEKS 42-104 ) : Patients receive vincristine sulfate IV day 1 , 29 , 57 ; dexamethasone IV PO BID day 1-5 , 29-33 , 57-61 ; methotrexate IT day 1 ; methotrexate PO day 8 , 15 , 22 , 36 , 43 , 50 , 64 , 71 , 78 ; mercaptopurine PO day 8-28 , 36-56 , 64-84 . Treatment repeat every 12 week 2 year diagnosis . A safety/activity phase conduct separately intermediate-risk ( IR ) high-risk ( HR ) patient identify safe , tolerable , biologically active dose lestaurtinib combine chemotherapy backbone . Once tolerable/active dose lestaurtinib identify IR patient , subsequent IR patient eligible proceed efficacy phase , randomize ( non-randomly assign 7/16/2014 ) chemotherapy without lestaurtinib . HR patient separately proceed randomize efficacy phase tolerable/active dose identify HR stratum . IR HR patient randomize ( non-randomly assign 7/16/2014 ) 1 2 post-induction therapy regimen ( post-induction therapy B C ) . POST-INDUCTION THERAPY B : ( chemotherapy IR/HR patient classify MLL-R ; age &gt; = 90 day diagnosis ) : INDUCTION INTENSIFICATION ( WEEKS 6-9 ) : Patients receive high-dose methotrexate , leucovorin calcium , cyclophosphamide , etoposide , filgrastim post-induction therapy A induction intensification . Patients morphologic remission proceed re-induction . ( Retired 7/16/2014 ) RE-INDUCTION ( WEEKS 10-12 ) : Patients receive vincristine sulfate , daunorubicin hydrochloride , cyclophosphamide , pegaspargase asparaginase , dexamethasone , triple IT chemotherapy , filgrastim post-induction therapy A re-induction . ( Retired 7/16/2014 ) CONSOLIDATION ( WEEKS 13-19 ) : Patients receive high-dose methotrexate , leucovorin calcium , triple IT chemotherapy , etoposide , cyclophosphamide , high-dose cytarabine , pegaspargase asparaginase , filgrastim post-induction therapy A consolidation . ( Retired 7/16/2014 ) CONTINUATION I ( WEEKS 20-49 ) : Patients receive vincristine sulfate IV 1 minute day 1 week 20 , 24 , 33 , 37 , 46 ; dexamethasone PO IV BID day 1-5 week 20 , 24 , 33 , 37 , 46 ; triple IT chemotherapy day 1 week 20 , 24 , 33 , 37 , 46 ; methotrexate IV day 1 week 21-23 , 25-26 37-45 ; mercaptopurine PO day 1-7 week 21-23 , 25-26 37-45 ; etoposide IV 2 hour day 1-5 week 27 ; cyclophosphamide IV 2 hour day 1-5 week 27 : high-dose cytarabine IV 3 hour every 12 hour day 1 2 week 30 ; pegaspargase asparaginase IM day 2 week 30 : filgrastim SC IV begin day 3 week 30 continue blood count recover . ( Retired 7/16/2014 ) CONTINUATION II ( WEEKS 50-104 ) : Patients receive vincristine sulfate , dexamethasone , IT methotrexate , methotrexate PO , mercaptopurine PO post-induction therapy A continuation II . Treatment repeat every 12 week 2 year diagnosis . ( Retired 7/16/2014 ) POST-INDUCTION THERAPY C : ( chemotherapy lestaurtinib IR/HR patient classify MLL-R ; age &lt; 90 day diagnosis ) INDUCTION INTENSIFICATION THERAPY ( WEEKS 6-9 ) : Patients receive high-dose methotrexate , leucovorin calcium , cyclophosphamide , etoposide , filgrastim post-induction therapy B induction intensification . Patients also receive lestaurtinib PO BID day 20-27 . Patients morphologic remission proceed re-induction . RE-INDUCTION ( WEEKS 10-12 ) : Patients receive vincristine sulfate , daunorubicin hydrochloride , cyclophosphamide , pegaspargase asparaginase , dexamethasone , triple IT chemotherapy , filgrastim post-induction therapy B re-induction . Patients also receive lestaurtinib PO day 5-20 . CONSOLIDATION ( WEEKS 13-19 ) Patients receive high-dose methotrexate , leucovorin calcium , triple IT chemotherapy , etoposide , cyclophosphamide , high-dose cytarabine , pegaspargase asparaginase , filgrastim post-induction therapy B consolidation . Patients also receive lestaurtinib PO day 20-27 31-42 . CONTINUATION I ( WEEKS 20-49 ) : Patients receive vincristine sulfate , dexamethasone , triple IT chemotherapy , methotrexate , mercaptopurine , etoposide , high-dose cytarabine , pegaspargase asparaginase , filgrastim post-induction therapy B continuation I . Patients also receive lestaurtinib PO day 2-6 week 20 24 ; day 27-41 week 27-29 ; day 45-56 week 30-32 . CONTINUATION II ( WEEKS 50-104 ) : Patients receive vincristine sulfate , dexamethasone , IT methotrexate , methotrexate PO , mercaptopurine PO post-induction therapy B continuation II . Treatment repeat every 12 week 2 year diagnosis . After completion study treatment , patient follow every 1-6 month 4 year annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must enrol Children 's Oncology Group ( COG ) ALL Classification Study ( AALL08B1 ) prior enrollment AALL0631 Patients must newly diagnose acute lymphoblastic leukemia ( ALL ) acute undifferentiated leukemia ( AUL ) ; patient Tcell ALL eligible ; patient bilineage biphenotypic acute leukemia eligible , provided morphology immunophenotype predominately lymphoid Patients mature Bcell ALL acute myelogenous leukemia ( AML ) NOT eligible Patients Down syndrome NOT eligible Patients must previously untreated exception steroid intrathecal chemotherapy ; systemic chemotherapy may administer ; patient receive prior steroid therapy eligible study ; amount steroid pretreatment affect initial induction assignment long patient meet eligibility criterion ; IT chemotherapy per protocol allow patient convenience time diagnostic bone marrow venous line placement avoid second lumbar puncture ; ( note : central nervous system [ CNS ] status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment ) ; systemic chemotherapy must begin within 72 hour IT therapy All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>